Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1537–1560 of 5,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Lung Cancer Clear all

Conditions: Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Gastrointestinal/Genitourinary Cancers, Neuroendocrine Tumors, Multiple Myeloma
Interventions: Cyclophosphamide, Fludarabine, Aldesleukin, Individual Patient TCR-Transduced PBL, Pembrolizumab (KEYTRUDA(R)); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years
Enrollment: 285 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Neoplasm Metastasis
Interventions: Bevacizumab, Pemetrexed, Vitamin B12, Folate, Dexamethasone; Drug
Lead sponsor: Heather Wakelee; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 4
States / cities: Stanford, California • Lebanon, New Hampshire • Voorhees Township, New Jersey + 1 more

Conditions: Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum, Cutaneous Melanoma, Non-Small Cell Lung Cancer
Interventions: GV20-0251, GV20-0251 and Pembrolizumab [KEYTRUDA®]; Biological
Lead sponsor: GV20 Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 9 more

Conditions: Chronic Obstructive Pulmonary Disease, Lung Cancer
Interventions: Pulmonary Rehab; Other
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: NSCLC Stage IV, ALK Fusion Protein Expression
Interventions: Peptide vaccine; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Solid Tumors
Interventions: Docetaxel, vantictumab; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Aurora, Colorado • Buffalo, New York • Cleveland, Ohio

Conditions: Colorectal Cancer, Non-Small Cell Lung Cancer
Interventions: GDC-1971, Osimertinib, Cetuximab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Lung Cancer
Interventions: 6-hydroxymethylacylfulvene; Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 48
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more

Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Interventions: CHS-388, Pembrolizumab, Toripalimab; Drug
Lead sponsor: Coherus Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Duarte, California • Los Angeles, California • San Francisco, California + 15 more

Conditions: Advanced Solid Tumors Cancer
Interventions: ABBV-368, ABBV-181; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 139 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 10
States / cities: La Jolla, California • Sacramento, California • Stanford, California + 7 more

Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma
Interventions: Iadademstat, Paclitaxel; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 3
States / cities: Buffalo, New York • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Non Small Cell Lung Cancer
Interventions: eribulin mesylate, pemetrexed, Eribulin mesylate (eribulin; E7389); Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 6
States / cities: Tucson, Arizona • Denver, Colorado • Fort Myers, Florida + 3 more

Conditions: Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor
Interventions: TNG456, abemaciclib; Drug
Lead sponsor: Tango Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: Scottsdale, Arizona • Irvine, California • Los Angeles, California + 11 more

Conditions: Lung Cancer, Lung Cancer Screening, Healthy Volunteers (HV), Unhealthy Volunteers
Interventions: Epigenetic Signature Assay; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Glen Burnie, Maryland

Conditions: Graft vs Host Disease
Interventions: Pentostatin; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 1 Month to 21 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 25
States / cities: Loma Linda, California • Oakland, California • Jacksonville, Florida + 22 more

Conditions: Home Air Radon Testing, Lung Cancer
Interventions: Public health infographic (AIM 3), Online health promotion intervention tailored by smoking status (AIM 3), Online health promotion intervention tailored by smoking status, plus reminder messages (AIM 3), Focus group with educational overview (AIM 1); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Breast Cancer, Head and Neck Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Hepatocellular Cancer, Colorectal Cancer, Gastric Adenocarcinoma, Melanoma, Advanced Cancer
Interventions: TTI-101; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Houston, Texas • San Antonio, Texas

Conditions: Lung Cancer
Interventions: Onartuzumab, Erlotinib, Paclitaxel, Carboplatin, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lung Cancer
Interventions: immunohistochemistry staining method, biopsy, surgery; Other · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 1,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2011
U.S. locations: 56
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 37 more

Conditions: Malignant Pleural Mesothelioma
Interventions: Pemetrexed/Cisplatin, Pleural Intensity Modulated Radiation Therapy, MRI; Drug · Radiation · Device
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2015
U.S. locations: 6
States / cities: Basking Ridge, New Jersey • Commack, New York • East White Plains, New York + 3 more

Conditions: Malignant Pleural Mesothelioma
Interventions: defactinib (VS-6063), Placebo; Drug
Lead sponsor: Verastem, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 344 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: San Francisco, California • Weston, Florida • Chicago, Illinois + 9 more

Conditions: Advanced/Metastatic Non-Small Cell Lung Cancer
Interventions: Ixabepilone, 32 mg/m^2, Paclitaxel, 200 mg/m^2, Carboplatin (area under the concentration curve [AUC] 6); Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: La Jolla, California • Baltimore, Maryland

Conditions: Lung Carcinoma
Interventions: Varenicline, Placebo, Tobacco Cessation Counseling; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 374
States / cities: Fairbanks, Alaska • Kingman, Arizona • Jonesboro, Arkansas + 236 more

Conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Gastroesophageal Adenocarcinoma, Urothelial Carcinoma, Pancreatic Ductal Adenocarcinoma
Interventions: Blood collection for research (next-generation sequencing [NGS]), Blood collection for research (HLA typing); Procedure
Lead sponsor: Gritstone bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 5
States / cities: Chicago, Illinois • New York, New York • Columbus, Ohio + 2 more

Search by objective public record fields.

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2 Trial of Bevacizumab in Combination With Pemetrexed

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

Accelerated Pulmonary Rehabilitation in the Preoperative Period

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

A Study of Vantictumab (OMP-18R5) in Combination With Docetaxel in Patients With Previously Treated NSCLC

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Signature Development and Validation Protocol for an Epigenetic Assay in Diagnosing Lung Cancer

Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children

Healthy Homes Study

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)

Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery

Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer

Management of Tobacco Treatment Intervention in Reducing Surgical Complications in Patients With Newly Diagnosed Lung Cancer Who Smoke Cigarettes

A Study of Personalized Neoantigen Cancer Vaccines